Agenus Inc. (NASDAQ: AGEN) announced the publication of Phase 1b clinical trial data for its drug combination botensilimab and balstilimab ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE